In the world of early stage investing, there exists a range of structures from the most founder friendly to the most investor friendly. The most investor-friendly structure involves some type of a ...

Duke Energy (DUK) announced the pricing of $1.3 billion in convertible senior notes due in 2029 through a private placement. This amount is higher than the previously stated $1 billion. The initial ...

You finally have investor interest. A couple of angels like the idea, one says “We usually do SAFEs,” another asks if you’re open to a convertible note, and suddenly you’re deep in legal blog posts at ...

For many early-stage startups, choosing between a convertible note and a SAFE (Simple Agreement for Future Equity) is one of the first critical legal and strategic financing decisions. While both ...

In the realm of biotech and pharmaceuticals, fundraising often plays a pivotal role in driving innovation and progress. Biotech and pharmaceutical companies, whether private startups or established ...

Convertible senior notes are hybrid debt instruments companies use to raise capital without immediate dilution while giving investors the opportunity to convert debt into equity under favorable ...

WATSONVILLE, Calif.--(BUSINESS WIRE)--Granite Construction Incorporated (NYSE: GVA) (“Granite”) today announced the pricing of its previously announced offering of $325 million aggregate principal ...

ATLANTA--(BUSINESS WIRE)--Repay Holdings Corporation (NASDAQ: RPAY) (“REPAY” or the “Company”) today announced that it has priced an offering of $260.0 million aggregate principal amount of its ...

GameStop is back in the news with another wave of shareholder dilution. The company announced plans to issue $1.3 billion of convertible senior notes with an additonal $200 million on the table as ...

Beyond Meat (BYND) announced that approximately 97% of its $1.15 billion in convertible notes due March 2027 were tendered by the early tender deadline for its exchange offer. This should buy Beyond ...

MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today ...